Funds › First Light Asset Management, LLC
First Light Asset Management, LLC
13F for Q2 2026, filed Aug 14, 2026. 31 positions worth $1.6B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of First Light Asset Management, LLC in the latest 13F quarter?
Using 13F.ai, how has First Light Asset Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of First Light Asset Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | NEO NeoGenomics, Inc. | 12.28M | $179.2M | 10.9% | +26.2% | 13F ↗ |
| 2 | SIBN SI-BONE, Inc. | 8.13M | $132.6M | 8.1% | +51.8% | 13F ↗ |
| 3 | AXGN Axogen, Inc. | 2.75M | $126.9M | 7.7% | -31.3% | 13F ↗ |
| 4 | Apogee Therapeutics Inc | 930,289 | $123.5M | 7.5% | +61.3% | 13F ↗ |
| 5 | PVLA Palvella Therapeutics, Inc. | 771,901 | $118.0M | 7.2% | -21.3% | 13F ↗ |
| 6 | TWST Twist Bioscience Corporation | 727,933 | $74.9M | 4.6% | -17.2% | 13F ↗ |
| 7 | ELVN Enliven Therapeutics, Inc. | 1.36M | $69.1M | 4.2% | +574% | 13F ↗ |
| 8 | GH Guardant Health, Inc. | 441,586 | $66.3M | 4.0% | +57.5% | 13F ↗ |
| 9 | MASS 908 Devices Inc. | 6.28M | $54.7M | 3.3% | +3.5% | 13F ↗ |
| 10 | AMLX Amylyx Pharmaceuticals, Inc. | 3.02M | $54.3M | 3.3% | -5.2% | 13F ↗ |
| 11 | WGS GeneDx Holdings Corp. | 783,923 | $53.8M | 3.3% | +223% | 13F ↗ |
| 12 | Simulations Plus Inc | 2.79M | $51.1M | 3.1% | +6.1% | 13F ↗ |
| 13 | TNDM Tandem Diabetes Care, Inc. | 3.38M | $51.1M | 3.1% | +157% | 13F ↗ |
| 14 | Crinetics Pharmaceuticals In | 1.36M | $50.9M | 3.1% | +24.9% | 13F ↗ |
| 15 | NPCE Neuropace, Inc. | 2.86M | $45.5M | 2.8% | +16.3% | 13F ↗ |
| 16 | EWTX Edgewise Therapeutics, Inc. | 1.10M | $44.5M | 2.7% | +9.3% | 13F ↗ |
| 17 | ANAB AnaptysBio, Inc. | 582,004 | $39.3M | 2.4% | -31.4% | 13F ↗ |
| 18 | TRVI Trevi Therapeutics, Inc. | 2.10M | $39.1M | 2.4% | New | 13F ↗ |
| 19 | SEPN Septerna, Inc. | 963,260 | $32.3M | 2.0% | +31.4% | 13F ↗ |
| 20 | TLSI TriSalus Life Sciences, Inc. | 6.55M | $29.8M | 1.8% | +29.3% | 13F ↗ |
| 21 | TECX Tectonic Therapeutic, Inc. | 800,726 | $27.5M | 1.7% | +23.6% | 13F ↗ |
| 22 | HCAT Health Catalyst, Inc | 12.81M | $25.5M | 1.5% | -0.5% | 13F ↗ |
| 23 | BFLY Butterfly Network, Inc. | 2.64M | $22.2M | 1.4% | -0.7% | 13F ↗ |
| 24 | ESTA Establishment Labs Holdings Inc. | 246,577 | $21.2M | 1.3% | -19.9% | 13F ↗ |
| 25 | PCVX Vaxcyte, Inc. | 345,157 | $20.1M | 1.2% | +143% | 13F ↗ |
| 26 | IRTC iRhythm Holdings, Inc. | 167,092 | $19.9M | 1.2% | -0.6% | 13F ↗ |
| 27 | OMCL Omnicell, Inc. | 452,324 | $18.8M | 1.1% | -7.7% | 13F ↗ |
| 28 | ATRC AtriCure, Inc. | 567,838 | $15.9M | 1.0% | -22.2% | 13F ↗ |
| 29 | KRMD KORU Medical Systems, Inc. | 3.39M | $14.2M | 0.9% | -10.1% | 13F ↗ |
| 30 | TCMD Tactile Systems Technology, Inc. | 462,562 | $13.8M | 0.8% | New | 13F ↗ |
| 31 | RYTM Rhythm Pharmaceuticals, Inc. | 85,765 | $9.5M | 0.6% | -1.6% | 13F ↗ |
Changes since Q1 2026
2 new, 16 added to, 13 trimmed, 6 exited, 0 unchanged. By estimated dollars.
New positions (2)
Added to (16)
| ELVN Enliven Therapeutics, Inc. | 1.36M | +574% | $58.8M |
| Apogee Therapeutics Inc | 930,289 | +61.3% | $46.9M |
| SIBN SI-BONE, Inc. | 8.13M | +51.8% | $45.3M |
| NEO NeoGenomics, Inc. | 12.28M | +26.2% | $37.2M |
| WGS GeneDx Holdings Corp. | 783,923 | +223% | $37.1M |
| TNDM Tandem Diabetes Care, Inc. | 3.38M | +157% | $31.2M |
| GH Guardant Health, Inc. | 441,586 | +57.5% | $24.2M |
| PCVX Vaxcyte, Inc. | 345,157 | +143% | $11.8M |
| Crinetics Pharmaceuticals In | 1.36M | +24.9% | $10.1M |
| SEPN Septerna, Inc. | 963,260 | +31.4% | $7.7M |
Trimmed (13)
| AXGN Axogen, Inc. | 2.75M | -31.3% | -$57.9M |
| PVLA Palvella Therapeutics, Inc. | 771,901 | -21.3% | -$31.9M |
| ANAB AnaptysBio, Inc. | 582,004 | -31.4% | -$18.0M |
| TWST Twist Bioscience Corporation | 727,933 | -17.2% | -$15.5M |
| ESTA Establishment Labs Holdings Inc. | 246,577 | -19.9% | -$5.2M |
| ATRC AtriCure, Inc. | 567,838 | -22.2% | -$4.5M |
| AMLX Amylyx Pharmaceuticals, Inc. | 3.02M | -5.2% | -$3.0M |
| KRMD KORU Medical Systems, Inc. | 3.39M | -10.1% | -$1.6M |
| OMCL Omnicell, Inc. | 452,324 | -7.7% | -$1.6M |
| RYTM Rhythm Pharmaceuticals, Inc. | 85,765 | -1.6% | -$157.2K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer